Urothelial Carcinoma Treatment Market Analysis

  • Report ID: 3912
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Urothelial Carcinoma Treatment Market Analysis

Treatment (Immunotherapy, Radiotherapy, Chemotherapy

The global urothelial carcinoma treatment market is segmented and analyzed for demand and supply by treatment into immunotherapy, radiotherapy, and chemotherapy. Out of the three types of treatments, the chemotherapy segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the introduction of more chemotherapeutic drugs which are being approved for use in the urothelial carcinoma treatment. Clinical trials are being conducted on a variety of systemic chemotherapies to determine which medicines or medication combinations are most effective at treating bladder cancer. The majority of the time, a pharmacological cocktail is more effective than a single medication. For instance, the use of cisplatin-based chemotherapy prior to major surgery for muscle-invasive bladder cancer is firmly supported by scientific research. Cisplatin is a chemotherapy drug used which is usually used to treat testicular, ovarian, bladder, head and neck, lung, and cervical cancer. In 2018, approximately 10 million out of 17 million new cases of cancer required chemotherapy globally.

End-user (Hospital Pharmacy, Retail Pharmacy)

The global urothelial carcinoma treatment market is also segmented and analyzed for demand and supply by end-user into hospital pharmacy, retail pharmacy, and others. Amongst these three segments, the hospital pharmacy segment is expected to garner a significant share. Hospitals are a critical part of the healthcare business and a significant source of revenue for the whole sector, which supports research and innovation. A hospital's uses cutting-edge medical technology to address complex medical situations. It is simpler and more convenient for patients with cancer or other diseases to acquire the recommended medications right on the hospital grounds when they are receiving treatment. On the other hand, private hospitals are increasingly being seen as needed to increase their specialization and cater to patients who need urgent medical attention, such as cancer and cardiovascular treatment.

Our in-depth analysis of the global market includes the following segments:

               By Type

  • Non-Invasive
  • Invasive Urothelial Carcinoma

              By Treatment

  • Immunotherapy
  • Radiotherapy
  • Chemotherapy

            By End User

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3912
  • Published Date: Jul 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of urothelial carcinoma treatment is estimated at USD 1.44 Billion.

The urothelial carcinoma treatment market size was valued at USD 1.21 Billion in 2023 and is expected to cross USD 15.1 Billion by the end of 2036, registering more than 21.4% CAGR during the forecast period i.e., between 2024-2036. Raising funding for research and development to develop novel cancer therapies and the growing awareness about bladder diseases are the major factors driving the market growth.

North America is likely to dominate majority industry share by 2036, attributed to increasing frequency of urothelial carcinoma cancer in the region.

Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Dendreon Pharmaceuticals LLC, Sanofi SA, F. Hoffmann-La-Roche AG, UroGen Pharma Ltd, Koninklijke Philips N.V., Olympus Corporation, AstraZeneca PLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample